A study in 790 men with metastatic hormone-sensitive prostate cancer treated with either androgen deprivation therapy (ADT) only or ADT plus docetaxel shows that quality of life (assessed, for example, using the Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire) of those receiving the combination therapy was worse at 3 months but better at 12 months than that of men receiving ADT only. Both patient groups reported a similar minimally changed quality of life over time.